Bio-Rad Laboratories, Inc.

Bio-Rad Laboratories, Inc.(BIO)の株式分析

$364.820

+2.408 (+0.66%)終値時点

Loading chart…
高値
368.540
始値
364.900
出来高加重平均価格
364.41
出来高
247.83K
時価総額
7.76B
安値
359.880
売買代金
90.31M
EV/EBITDA(TTM)
22.48

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories.

www.bio-rad.com

AI分析 of Bio-Rad Laboratories, Inc. (BIO)

中立

Bio-Rad Laboratories Inc is currently a hold. The stock is trading at $366.16, which is close to the analyst price target of $390, indicating limited upside potential at this moment. The RSI is at 44.39, suggesting it is nearing oversold territory, but not yet in a strong buy zone. The forward P/E ratio is 41.32, which is high, indicating that the stock may be overvalued compared to its earnings potential. The main risk is the recent decline in the Life Science segment, which reported a 4.1% decrease in sales year-over-year, reflecting challenges in the academic research market. Overall, while there are some positive indicators, the current price and valuation metrics suggest that it may be prudent to hold rather than buy at this time.

アナリスト評価(4)

-6.80% 下落余地
買い
4 買い
0 中立
0 売り
現在: 364.82
安値
340.00
平均
340.00
高値
340.00

RBC Capital

2026-08-07

目標株価

$390

アウトパフォーム

Wells Fargo

2026-05-25

目標株価

$310

Equal Weight

RBC Capital

2026-05-14

目標株価

$320

アウトパフォーム

Wells Fargo

2026-05-01

目標株価

$290

Equal Weight

Citi

2026-04-07

目標株価

$300

中立

バリュエーション指標

Bio-Rad Laboratories, Inc.(BIO)の現在の予想PERは41.32で、5年平均は33.15です。

予想PER

適正
5年平均 P/E
33.15
現在のP/E
41.32
割高
41.39
割安
24.91

予想EV/EBITDA

適正
5年平均 EV/EBITDA
20.62
現在のEV/EBITDA
22.48
割高
26.72
割安
14.52

予想PSR

適正
5年平均 P/S
4.01
現在のP/S
3.70
割高
5.33
割安
2.69

Alphio AI による BIO の価格シナリオ

シナリオ価格は本年の最終月次予想レンジです。確率はモデルの固定ウェイト(25 / 50 / 25)であり、保証ではありません。

強

強気

強気 · 25%BIO

$211.45

シナリオ価格

基

基本

基本 · 50%BIO

$204.69

シナリオ価格

弱

弱気

弱気 · 25%BIO

$154.89

シナリオ価格

BIO を保有するクジラ

F

First Pacific Advisors, LP

+ を保有BIO

+2.03%

3か月リターン

H

Hosking Partners LLP

+ を保有BIO

+1.54%

3か月リターン

A

Ariel Investments, LLC

+ を保有BIO

-3.36%

3か月リターン

D

Deerfield Management Company, L.P.

+ を保有BIO

-6.90%

3か月リターン

イベントタイムライン

2026-09-24 (ET)

06:30:00

Biodesix Advances Tumor-Informed and Tumor-Naive MRD Solutions

2026-08-04 (ET)

17:00:00

Bio-Rad Implements Restructuring Plan Estimated Costs Up to $90 Million

16:30:00

Company Expects 2026 Non-GAAP Revenue to Decline Approximately 3%

16:30:00

Bio-Rad Reports Q2 Revenue of $651M, Beating Expectations

2026-07-21 (ET)

10:30:00

Sartorius Shares Drop After Competitor Earnings Report

ニュース

BIO のよくある質問 — Alphio AI が回答

Bio-Rad Laboratories, Inc. is engaged in developing, manufacturing, and marketing a range of products for the life science research and clinical diagnostics markets. The Company offers a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components. It operates through two segments: Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets instruments, systems, reagents, and consumables used for biological research, biopharmaceutical production processes, food testing regimes, and science education. Its Clinical Diagnostics segment designs, manufactures, markets and supports test systems, informatics systems, test kits and specialized quality controls that serve clinical laboratories in the global diagnostics market. These products are sold to hospital laboratories, diagnostic reference laboratories, transfusion laboratories, and physician office laboratories. It operates in the Healthcare sector (LABORATORY ANALYTICAL INSTRUMENTS industry).

Bio-Rad Laboratories Inc is currently a hold. The stock is trading at $366.16, which is close to the analyst price target of $390, indicating limited upside potential at this moment. The RSI is at 44.39, suggesting it is nearing oversold territory, but not yet in a strong buy zone. The forward P/E ratio is 41.32, which is high, indicating that the stock may be overvalued compared to its earnings potential. The main risk is the recent decline in the Life Science segment, which reported a 4.1% decrease in sales year-over-year, reflecting challenges in the academic research market. Overall, while there are some positive indicators, the current price and valuation metrics suggest that it may be prudent to hold rather than buy at this time.

4 analysts cover BIO: 4 rate it Buy, 0 Hold and 0 Sell. The average price target is 340.00.

コミュニティ

もっと見る ↗
TrendCircuit2026/9/13

Didn't do anything, just went to the bathroom, and when I came back the chart had already done the work for me. When the market dumped early on, $BIO's bounce looked weak no matter how you read it. Every step down from the high came with volume, but the rebound kept getting lighter. Overhead trapped positions were pressing down clearly, funds just wanted to use the bounce to exit, nobody really wanted to buy. I was watching the short direction at 0.03161, with protection set at the upper edge of the bounce platform. At the time I only reminded one thing: don't try to catch a bounce in the early stage of a breakdown. If your hands are itching, go to the bathroom and wash your face. Came back and refreshed, price had already reached 0.02549, position return sitting at +1376.01%. Everyone on board should be feeling good. I took 80% off the table first, moved protection on the remaining 20% to breakeven. If it keeps dropping, let it drop, if it breaks the previous low there's another leg to capture; if it bounces back, this trade won't turn from profit into loss. Risk control done upfront is called being rational; cutting after losses is called cutting your losses. Don't chase shorts now, wait for a bounce to a structural level before acting. If the next shot doesn't come, wait patiently. The market won't only open its door once. $ADA $ETH

もっと見る
TrendCircuit2026/9/11

I was about to go vent on the forum, then I checked my balance and decided to let it go. The market is always right 😮💨 When the morning session dumped, $BIO bounced and it actually looked decent for a moment. But the more I watched the order book, the more something felt off. Every push up came with no volume, a classic sign of weak follow-through. That kind of bounce looks lively, but nobody is actually stepping in to buy. The chart keeps teaching you lessons, most people just choose to sleep through class. I went ahead and opened a short at 0.03161. Someone said I was late to the trade. I didn't bother arguing, just waited for the result. Price just dropped to 0.02504, and my position PnL hit +1479.26%. It was slow at first, but once it moved, it really moved. Feels good. Nailing the rhythm matters more than anything 😎 I took 80% off the table and moved my stop on the remaining 20% back to breakeven. Whether it bounces from here or keeps grinding down, I won't be stressed either way. The prerequisite for compounding is staying alive. The shortcut to getting rich is usually going to zero. I'd rather miss a limit-up than try to catch a falling knife and end up with bloody hands. Don't chase here. Chasing at key levels is how you get hurt. I'll wait for the next signal. $XRP $LAB

もっと見る
TrendCircuit2026/9/11

I opened the charts this morning, rubbed my eyes, and gave myself a little slap to make sure I wasn't seeing things. No trades, no analysis, just pure luck and stubbornness. Saying that record out loud feels embarrassing, but honestly, it feels great. Panic comes from having no plan, losses come from overthinking. I just sat there quietly watching it perform. When the screen was full of green, some people were panicking, but I found it interesting. Thinking back to a few days ago, the last look before bed, the trend clearly had no strength, the bounce was weak, and volume wasn't following at all. Funds wanted to push it up, but even they didn't dare enter. The fake breakout smell was right in your face. My only thought at the time was that this kind of bounce wouldn't last past the third watch. Short above 0.03161, now $BIO is at 0.02458, unrealized gain +1573.54%. This one was just the market in a good mood, handing money over. But even with the win, position management still matters. Everyone note the position moves: take profit on 80% first to lock in gains, move the stop on the remaining 20% to near cost, and let it run a bit. Risk control done upfront is called being rational; cutting after a loss is called a last resort. Don't get jealous of this level now, this isn't the time to chase. If you missed the rhythm, you missed it. Wait for a more comfortable spot next round. I'll keep watching the charts and call it as soon as there's a signal. The market never lacks opportunities, it lacks the patience to wait. Everyone keep your hands tied. $SNDK $SOL

もっと見る
登録またはログインして議論に参加

本ページは調査目的であり、投資助言ではありません。モデルは誤ることがあります。過去の実績は将来の成果を保証しません。

取引を始める